Pair page
Semaglutide with Survodutide
Mechanism-tag overlap and published literature for Semaglutide and Survodutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
glp-1-receptor-agonistmetabolic
glucagon-glp-1-receptor-dual-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Semaglutide and Survodutide have published these mechanism-level observations. Not a co-administration recommendation.
Semaglutide is a GLP-1 monoagonist; survodutide provides overlapping GLP-1 activity plus glucagon agonism. These are alternatives rather than a stack. Sequential use — e.g., semaglutide first for weight-loss initiation, then transition to survodutide for continued weight loss and hepatic-fat clearance — is plausible once survodutide is approved, but has not been studied.
Quick facts
Semaglutide
Survodutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | Semaglutide | Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209. PMID 38785209 | human trial |
| 2023 | Semaglutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PMID 37952131 | human trial |
| 2022 | Semaglutide | Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PMID 36216945 | human trial |
| 2022 | Semaglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. PMID 35015037 | human trial |
| 2021 | Semaglutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PMID 33567185 | human trial |
| 2021 | Semaglutide | Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PMID 33667417 | human trial |
| 2021 | Semaglutide | Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476. PMID 33625476 | human trial |
| 2021 | Semaglutide | Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728. PMID 33755728 | human trial |
| 2021 | Semaglutide | Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364. PMID 33185364 | human trial |
| 2019 | Semaglutide | Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300. PMID 31186300 | human trial |
| 2016 | Semaglutide | Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186. PMID 27633186 | human trial |
| 2019 | Semaglutide | Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702. PMID 31031702 | mechanism / discovery |
| 2024 | Survodutide | Wharton S, le Roux CW, Kosiborod MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity (Silver Spring). 2024. | human trial, Phase 3 |
| 2023 | Survodutide | Boehringer Ingelheim. Phase III studies — survodutide in obesity and overweight. Boehringer Ingelheim corporate press release and investor materials, 2023–2025. | human trial, Phase 3 |
| 2025 | Survodutide | Le Roux CW, et al. Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial. Diabetes Obes Metab. 2025. doi:10.1111/dom.1… | human trial, Phase 2 |
| 2024 | Survodutide | Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. doi:10.1016/S2213-8587(… | human trial, Phase 2 |
| 2024 | Survodutide | Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Martins EB, Walker M, Oldham P, Starova B, Ogawa W, Wong VW, Ratziu V, Younes R, Hosseini-Tabatabaei A, Loomba R. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J M… PMID 38847460 | human trial, Phase 2 |
| 2023 | Survodutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (F… PMID 37366315 | human trial, Phase 2 |
| — | Survodutide | ClinicalTrials.gov. NCT04667377 (Phase 2 obesity); NCT04771273 (Phase 2 MASH, study 1404-0043); NCT06066879 (SYNCHRONIZE-1); NCT06066892 (SYNCHRONIZE-2). | human trial, Phase 2 |
| 2023 | Survodutide | Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Unseld A, Hennige AM. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes… | human trial, Phase 1 |
| 2016 | Survodutide | Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51-62. PMID: 27411008. (Foundational review on multi-receptor agonism rationale including GLP-1/glucagon.) PMID 27411008 | human study |
| 2022 | Survodutide | Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hennige AM, Hamilton B, Hennig R, Dux M, Hamprecht B, Bierwisch D, Neubauer H, Tschank G, Stengelin S, Redemann N, Wiedenmann A, Pagler T, et al.… | preclinical, in vivo |
| 2024 | Survodutide | Loomba R, Hartman ML, Sanyal AJ. Two Trials of Therapeutics for MASH with Liver Fibrosis. Reply. N Engl J Med. 2024;391(15):1462-1463. PMID: 39413388. PMID 39413388 | research article |
| 2024 | Survodutide | Polyzos SA. Two Trials of Therapeutics for MASH with Liver Fibrosis. N Engl J Med. 2024;391(15):1461. PMID: 39413385. PMID 39413385 | research article |
Related pair pages
More research context
Frequently asked
Have Semaglutide and Survodutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Semaglutide and Survodutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Semaglutide and Survodutide share?
Semaglutide and Survodutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Semaglutide and Survodutide?
Semaglutide: Approved (2017). Survodutide: Not approved; Phase 3. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Semaglutide and Survodutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Semaglutide profile and the Survodutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026